

SEARCH... 
[HOME](#) [ABOUT US](#) [TECHNOLOGY](#) [PEOPLE](#) [NEWS & PUBLICATIONS](#) [LINKS](#)


NEWS & PUBLICATIONS

[PRESS RELEASES](#)
[PUBLICATIONS](#)

PRESS RELEASES

A list of the most recent press releases issued by TREVENTIS Corporation are shown below. If you click on any listing, it will open to display the full text of the release. (Click again to close).

[DECEMBER 14, 2010 – TREVENTIS Corporation Moves to New Facilities in NRC Incubation Space](#)

TREVENTIS Corporation Moves to New Facilities in NRC Incubation Space Company Represents Engine of Economic Growth Through Partnership with Government, Academia and Industry

December 14, 2010 – Halifax, NS – TREVENTIS Corporation announced today that it is up and running in its new space at the National Research Council- Institute for Marine Biosciences (NRC-IMB) Industrial Partnership Facility (IPF), 1411 Oxford Street, Halifax. The Company represents a potential engine of growth in Atlantic Canada the result of partnerships with government, academia and industry.

Though the auspices of the National Research Council- Institute for Marine Biosciences (NRC-IMB), TREVENTIS was able to open laboratories and offices at the NRC's Industrial Partnership Facility (IPF) incubation space in downtown Halifax. This was facilitated by a recently awarded grant from NRC's Industrial Research Assistance Program (IRAP). Initially, employing five scientific staff members, TREVENTIS plans to expand both facilities and staff as funding and success in its research and development permit.

TREVENTIS Corporation was originally founded by a group of scientists at Dalhousie University, three of whom have recently won prestigious awards. They include Donald F. Weaver, MD, PhD recent winner of 2009 Prix Galien Research Award for his groundbreaking efforts to design novel drug therapies to treat chronic neurological disorders such as Alzheimer's disease; Christopher Barden, PhD winner of the Discovery Award as "Emerging Professional" for his work in computer aided drug design and; Sultan Darvesh, MD, PhD who received one of three nominations of the Discovery Award in the category of "Professional of Distinction" for his work and world-wide recognition in the field of butyrylcholinesterase (BuChE) as a diagnostic and therapeutic target in diseases of the brain.

Research at Dalhousie University lead to the elucidation of a new drug target for halting progression of Alzheimer's disease (AD) and other neurological disorders. The technology was assigned to TREVENTIS which was established to focus on drug development at their new facilities. In addition to the grant from IRAP, TREVENTIS is supported by financing from venture capital and private investors.

"This is a model of how biotechnology can grow and expand in Atlantic Canada," said Dr. Weaver. "TREVENTIS represents a multi-faceted collaboration between university, supportive government programs like the NRC and IRAP as well as industry, resulting in new, high paying, jobs to expand

the province's economic base."
About TREVENTIS Corporation

TREVENTIS Corporation a Canadian/American biotechnology company has research operations in Halifax, Nova Scotia, Canada and offices in Pennsylvania, USA. The company is focused on the discovery and early stage development of disease modifying, small molecule drugs for Alzheimer's and other protein misfolding diseases such as Parkinson's and Huntington's disease. In addition to its therapeutics programs, TREVENTIS has a novel approach to the development of diagnostics for early diagnosis and monitoring treatment effects in Alzheimer's disease, MS and primary brain tumors.

Contact:
L. William McIntosh
TREVENTIS, Chairman and CEO
Phone: 610-488-6081
wmcintosh@treventis.com

DECEMBER 16, 2009 – Treventis Scientific Founder Donald Weaver, MD, Named 2009
Recipient of Prix Galien Canada Award for Outstanding Achievement in Development of New
Medicines for Alzheimer's Disease

copyright © 2013 TREVENTIS Corporation